Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

rituximab and hyaluronidase

(rih-TUK-sih-mab … HY-al-yoo-RAH-nih-days)
A combination of two drugs used to treat adults with certain types of follicular lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukemia. Rituximab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Rituximab and hyaluronidase can be given in less time than rituximab alone, which is given as an infusion. Also called Rituxan Hycela.
More Information
Search NCI's Dictionary of Cancer Terms